Clinical Trials Specialist in Developmental Therapeutics

发育治疗学临床试验专家

• 批准号: 10640593
• 负责人: Nobuko Hijiya
• 金额: $ 17.59万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-05 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10640593
• 关键词: Child; Childhood; Childhood Leukemia; Clinical Research; Clinical Trials; Collaborations; Developmental Therapeutics Program; Disease remission; Dose; Faculty; Goals; Lead; Leadership; Marketing; Medical Students; Mentors; Methods; Myeloproliferative disease; Nursing Research; Pediatric Oncology; Pediatric Oncology Group; Physicians; Positioning Attribute; Research; Research Personnel; Role; Specialist; Therapeutic Agents; Therapeutic Clinical Trial; Therapeutic Studies; Therapeutics Committee; Training; Tyrosine Kinase Inhibitor; improved; interest; minority patient; next generation; novel; novel therapeutics

Project Summary The planned activities describe a set of efforts that will build upon my interest in developmental therapeutics and childhood leukemias. I will lead a team of physicians, research nurses, clinical research coordinators in the Pediatric Oncology and Developmental Therapeutics (DVL) Program at the HICCC and develop a portfolio of clinical trials, which includes NCI-sponsored studies. My goal is to increase the number of accruals to the DVL clinical trials, which is already excellent, by expanding with marketing efforts and also grow the portfolio of clinical trials at HICCC. I will continue my involvement in the Children’s Oncology Group (COG) Myeloid Disease Committee and Developmental Therapeutics Committee. I will carry on my efforts in my current PI or co-PI positions for open trials, i.e. the COG AAML1921 and AAML18P1 studies. I will develop a new COG study to evaluate a novel method of dose de-escalation of tyrosine kinase inhibitors before treatment-free remission in children with CML working with a junior faculty. In addition, I hope to identify barriers to the accrual of minority patients in pediatric developmental therapeutics studies and institute a plan to improve it. I am devoted to mentoring and training young faculty who will develop next generation research in pediatric oncology. I will continue my efforts to train residents and fellows interested in pediatric oncology. I will help junior faculty to establish their roles at HICCC/CUIMC and also expand their academic opportunities in cooperative groups and collaborations with outside investigators.

项目摘要 计划的活动描述了一系列的努力，将建立在我对发展治疗学的兴趣之上 和儿童白血病我将领导一个由医生、研究护士、临床研究协调员组成的团队， 儿科肿瘤学和发育治疗学（DVL）计划，并制定一个组合， 临床试验，包括NCI申办的研究。我的目标是增加DVL的应计项目数量 临床试验，这已经是很好的，通过扩大与营销工作，也增加了临床组合 审判在CIMCC。我将继续参与儿童肿瘤学小组（COG）的骨髓疾病研究 委员会和发展治疗委员会。我将继续我的努力，在我目前的PI或合作PI 开放试验的位置，即COG AAML 1921和AAML 18 P1研究。我将开发一个新的COG研究， 评估一种在无治疗缓解前降低酪氨酸激酶抑制剂剂量的新方法， 与一名初级教员一起工作的CML儿童。此外，我希望找出阻碍少数族裔累积的障碍， 儿童发育治疗学研究中的患者，并制定计划来改善它。 我致力于指导和培训年轻的教师谁将发展下一代的儿科研究 肿瘤学我将继续努力培养对儿科肿瘤学感兴趣的住院医师和研究员。我会帮助朱尼尔 教师建立自己的角色在cnccc/CUIMC，也扩大了他们的学术机会，在合作 与外部调查人员合作。